Automatized and combined HIV, HBV, HCV, and syphilis testing among illegal gold miners in French Guiana using a standardized dried blood device

Amandine PISONI[1], Elisa REYNAUD[2], Maylis DOUINE[3], Louise HUREAU[3], Carmen ALCOCER CORDELLAT[2], Roxane SCHAUB[3], Dennis POLAND[4], Richard MONKEL[4], Joan LOMMEN[4], Konstantin YENKOYAN[5], Mathieu NACHER[3], Edouard TUAILLON[1*]

1. Pathogenesis & Control of Chronic and Emerging Infections, Institut National de la Santé et de la Recherche Médicale (INSERM), U1058, Établissement Français du Sang (EFS), Montpellier University and Laboratory of Virology, Centre Hospitalier Universitaire de Montpellier, France.
2. Montpellier University Hospital, Montpellier, France
3. Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital, Epidemiology of Tropical Parasitoses, EA 3593, Universite de Guyane, Cayenne, French Guiana.
4. Labonovum, Limmen, Netherlands.
5. Department of Biochemistry, Yerevan State Medical University M. Heratsi, Yerevan 0025, Armenia

*Corresponding author : Pr. Edouard Tuaillon,
Centre Hospitalier Universitaire de Montpellier,
Laboratoire de Virologie Lapeyronie,
371 avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.
Email : e-tuaillon@chu-montpellier.fr
Tel : +33 4 67 33 83 40 Fax: +33 4 67 33 83 34

Keywords: HIV, hepatitis B, hepatitis C, syphilis, vulnerable population, Dried Blood Spot

Abstract:

Background: Blood spotted onto filter paper can be easy collected outside healthcare facilities and shipped to central laboratory for serological testing. However, dried blood testing generally requests manual processing for elution. In this study, we used a standardized blood collection device combined with an automatized elution system to test illegal gold miners living in French Guiana for HIV, HBV, HCV and syphilis.

Material and Methods: We included 378 participants in five resting sites of illegal gold mining. Serological status was determined by testing serum samples. Blood collected on the Ser-Col device (Labonovum), was eluted using an automated system (SCAUT Ser-Col automation, Blok System Supply) and an automatized analyzer (Alinity i, Abbott). Ser-Col results were compared to serum considered as the reference, and dried blood spot samples were processed manually.

Results: Two participants tested positive for HIV (0.5%), eight tested positive for hepatitis B surface antigen (HBsAg), four were weakly positive for anti-HCV antibodies (1%) but negative for HCV RNA, and 47 tested positive for syphilis (12.4%). We observed a full concordance of Ser-Col and DBS results for HIV diagnosis compared to serum results. Ser-Col and DBS samples tested positive in seven HBsAg carriers and negative for one participants having a low HBsAg level in serum (0.5 IU/mL). Three hundred and sixty-eight participants uninfected by HBV tested negative for HBsAg (99.5%). Two Ser-Col samples and two other DBS samples positive tested positive in HBV uninfected participants (false positive results with low S/CO indexes). All participants tested negative for HCV in Ser-Col and DBS samples, including in dried blood samples from the four participants tested low positive for HCV antibodies and HCV RNA negative in serum. The threshold of the treponemal assay was optimized for dried blood sample testing. Among syphilis seropositive participants, 35 (74.61%) tested positive for treponemal antibodies in Ser-Col and DBS samples. Among participants seronegative for syphilis, 326 (98.4%) and 325 (98.1%) tested negative in Ser-Col and DBS samples, respectively.

Conclusion: The Ser-Col method allows automatized dried blood testing of HIV, HBV, HCV and syphilis with performances comparable to DBS. Automated approaches to test capillary blood transported on dried blood devices may facilitate large scale surveys and improve testing of populations living in remote areas for infectious diseases.

Introduction

Reducing the burden of infectious diseases requires a global approach, without leaving underprivileged people aside. To date, access to reliable diagnosis of infectious diseases remains insufficient for a large part of the world's population. Migration, forced displacement of populations, weak infrastructures and distance from the health system are common unfavorable health factors. The lack of in vitro diagnostic tools contributes largely to the mortality and morbidity induced by infectious diseases in resource-limited countries [1]. Low number of laboratories and poor logistical infrastructure are a major problem in many of these countries. Laboratory equipment defined by WHO as essential for basic service readiness is also insufficient [2]. The weakness of human resources - health professionals and biologists - should also be underlined [3].

Capillary blood sampling performed outside healthcare facilities is one of the strategies to improve screening of hard-to-reach and key populations. DBS testing programs using dried blood spot (DBS) have been implemented for several years, targeting intravenous drug users [4], sex workers [5], homeless populations [6], migrants and men who have sex with men [7]. Today, DBS sampling is considered by the WHO as a possible alternative to serum/plasma to improve access to HIV, HBV and HCV screening and therapeutic monitoring. However, DBS has several limitations such as a lack of standardization of blood sampling and elution, and the manual processing of DBS cards. These constrains restrict DBS set up in clinical laboratories.

In French Guiana, about 10,000 illegal gold miners, mainly Brazilians (95%), work on more than 700 different mining sites located in the primary forest [8]. This neglected population presents a poor state of health [8]. People working on gold panning sites are particularly exposed to vector-borne diseases, including malaria [9] and leishmaniasis [8]. Data also suggest a higher prevalence of sexually transmitted infections HIV, hepatitis B (HBV) and syphilis than in other populations of French Guiana [10]. Having sex for presents or money is frequent in gold mining sites [10, 11]. According to a survey carried out in the city of Cayenne in French Guiana, transactional sex may contribute for 45% of HIV cases in men and 10.7% in women [12]. In a study carried out on the gold sites of French Guiana about 10% of women declared having already had a sex work activity [8].

In this study, we used an innovative blood collection device combined with an automatized elution system to test illegal gold miners living in French Guiana for HIV, HBV, HCV and syphilis.

Material and Methods

Study design

This study is part of the "SCAUT" study a EU-funded research projects (from finger to laboratory: personalized and automated serum collection for laboratory diagnostics). Participants were adults working in an illegal gold mining sites in French Guiana, (NCT03695770). Participants were included after having provided informed written consent. Testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis were offered at the resting site less than seven days after leaving the mining sites. Samples were send by canoe or car from the resting site to the hospital center of Cayenne and then to the Montpellier University Hospital to be tested. Results were communicated within two weeks on each site during the post-test counselling.

Sample processing

The processing of blood collected on the Ser-Col device (Labonovum, Netherlands) was performed using an automated system (SCAUT Ser-Col automation, Blok System Supply, Netherlands). The Ser-Col device contains a microfluidic paper separating plasma from whole blood. The automated system performed the elution from dried plasma contained in one centimeter of paper in 100μL of Ser-Col buffer.

Blood spotted onto Whatman 903™ Protein Saver Card (Whatman GmbH, Dassel, Germany) was dried at ambient temperature for at least 24h. DBS processing and elution was manual. One punch 6 mm of diameter was eluted in 100μL of phosphate-buffered saline.

Biological analysis

HIV p24/antibodies, HBsAg, anti-HCV antibodies, and anti-treponemal antibodies were assessed using fully automated chemiluminescence immunoassays (Alinity i, Abbott, IL, USA). Sample tested positives for HIV were confirmed using a rapid confirmatory assay based on immune-chromatography and automated reading (Geenius™ HIV1/2 Confirmatory Assay, Bio-Rad, France). Serum samples positive for anti-treponemal antibodies were tested by a Rapid Plasma Reagin Assays (ASI RPR, Arlington Scientific Inc.). All assays were done in accordance with the manufacturer's instructions

Data analysis and statistical methods

The HIV, HBV, HCV and syphilis status of participants was established by testing serum samples. Ser-Col results was compared to serum results considered as the reference. Ser-Col results were also compared to results obtained using the DBS considered as the reference sampling method using dried blood. Receiver operating characteristic curves (ROCs) were used to identify the positive threshold of

anti-treponemal antibodies in Ser-Col and DBS. Spearman's non-parametric test was used to assess correlation between results of anti-treponemal antibodies in Ser-Col and DBS, versus serum. Data results were analyzed using GraphPad Prism 9.3.1 (GraphPad Prism Software Inc.).

Results

We included 378 participants in five resting sites of illegal gold mining, 276 men and 102 women. The median (IQR) age was 39 years (31-48).

We first tested participants for HIV, HBV, HCV and syphilis infections using serum to determine their infection status for these infections. Two participants tested positive for HIV. HIV infection was confirmed with the Geenius test. The pattern of antibodies showed IgG directed against gp160, gp41, p24 and p31 (low signal) of HIV-1 for the first subject and gp160, gp41, p24 with no p31 antibodies for the second one. We did not observe any reactivity for HIV-2 antigens (gp140, gp36). Eight participants had HBV infection demonstrated by the presence of HBsAg. One subject had a weakly positive result with an S/CO of less than 10, corresponding to an HBsAg concentration of 0.5 IU/mL. Four subjects tested positive for anti-HCV antibodies, but all had index values close to the threshold of positivity. In addition, all of them tested negative for HCV RNA suggesting a recovered hepatitis C or false positive result. 47 subjects tested positive for syphilis using the treponemal test, (S/CO: 1.03 to 19.59). Among participants tested positive for treponemal antibodies, 13 (27.6%) tested also positive using the non-treponemal test, suggesting an active stage of infection or a recently treated infection. RPR dilution titers were 1:2 for five participants, 1:4 for six, 1:8 for one, 1:32 for one.

Then, the Ser-Col samples were tested for HIV, HBV, HCV and syphilis after automated elution. The eluates were assessed directly on the Abbott system without transfer into a secondary tube. All of the Ser-Col samples from HIV-seronegative subjects tested negative with low index values, leading to a specificity of 100%. Two subjects diagnosed with HIV infection were found positive using the Ser-Col device. The HIV confirmatory test was positive but with a partial agreement between Ser-Col and serum results. Seven of eight HBsAg carriers tested positive when using the Ser-Col device. The Ser-Col sample with the lowest HBsAg concentration in the paired serum sample (0.5 IU/mL) tested negative. Two Ser-Col samples from HBsAg negative participants had signal over the cut-of and were considered as false positive. The S/CO were close to the positive threshold. All HCV seronegative participants were also found negative for anti-HCV antibodies using the Ser-Col device. The four participants with HCV Abs +/RNA- pattern were found negative using the Ser-Col device. All Ser-Col samples from participants seronegative for anti-treponeme antibodies in serum tested negative. 20 out of 47 (42.5%) participants tested positive for anti-treponemal antibodies in serum had S/CO results below the threshold of the

manufacturer. The signal on cut off index was significantly higher in participants who tested positive for anti-treponemal antibodies in the serum. We established an optimized positive threshold based on a ROC curve. The best compromise was reached with a S/CO threshold of 0.28 instead of 1, corresponding to a sensitivity of and a specificity of 74.61% and 98.4% respectively. The AUC was 95.17 with this new threshold.

Finally, DBS samples were tested for HIV, HBV, HCV and syphilis. Punching and elution steps were performed manually. We observed identical screening results for HIV using DBS. The p31 band bands were also missing on DBS sample of the first and second HIV positive participants. As for Ser-Col samples, the sample with the lowest HBsAg concentration tested negative using the DBS. Two DBS samples collected from HBsAg negative participants had S/CO over the positive threshold. These samples were different from those found false positive using the Ser-Col samples. 23 out of 47 (48.9%) participants tested positive for anti-treponeme antibodies in serum had S/CO results below the threshold of the manufacturer. The ROC curve for the screening of anti-syphilis antibodies led to an AUC of 95.25, with a sensitivity of and a specificity of 73.91% and 98.08% respectively with the threshold of 0.28.

Discussion

Our study shows the feasibility of serological screening for sexually transmitted infections in a vulnerable population living in remote areas using standardized dried blood device and a full automatized processing. The clinical performance of the assays using the Ser-Col device appeared as good as using DBS but overcomes some of the limitations related to DBS processing. This approach allows combined screening for HIV, HCV, HBV and syphilis infections on blood collected outside health care facilities in resting sites of gold mining.

French Guiana has the highest prevalence of HIV and HBV among French regions [13, 14]. The HIV, HBV, HCV and syphilis prevalence observed in our study are consistent with those previously reported in this population [10]. With the exception of syphilis, the number of positive cases was relatively low, which leads to imprecise estimates of prevalence. These figures are close to HIV, HBV and HCV prevalence estimations in French Guiana. The prevalence of HIV has been estimated at 1.5% [13], HBV 2.96% and HCV infection 0.67% [14]. A low proportion of persons living with HIV and viral hepatitis are unaware of their infection status in remote areas and vulnerable population [15]. It is of primary importance to increase the frequency of screening for HIV, HBV and HCV infections. Capillary blood

sampling and dried blood transportation could facilitate large scale health surveys. This type of population testing has been carried out on DBS, for example for viral hepatitis [16] or SARS-CoV-2 [17].

This field study was carried out on a difficult terrain. The population of illegal gold miners in French Guiana consist of migrants living far from transport networks and health infrastructures in a harsh tropical environment. In this study, sampling was done close to the field and in vitro diagnosis were performed centrally laboratory certified ISO 15189 for HIV, HBV, HCV and syphilis testing using a high-throughput serological platform. The sample transportation from the field to a central laboratory is facilitated when using dried blood because there is no risk of the biological fluid spilling and no risk of virus transmission. Serological and molecular tests on DBS have shown satisfactory analytical performance for HIV and viral hepatitis [18, 19]. The DBS is recommended by WHO for diagnosis of HIV and viral hepatitis B and C to improve access to in vitro diagnosis of populations with poor access to serum tests [20, 21]. Nevertheless, the DBS suffers from significant limitations that hamper its use, including the lack of standardization of the sample and the absence of automation of the pre-analytical steps: punching, transfer and elution. The manual processing of DBS is a source of error and limits its integration in medical laboratories. The Ser-Col device and its automated processing overcome these limitations.

In our study, the screening on Ser-Col samples presents a high specificity, identifying HIV and HBV infections with exception of a weakly HBsAg positive sample. Two Ser-Col samples were false positive for HBsAg but with low S/CO values. The specificity for HCV appeared also high but the sensitivity could not be calculated since all participants tested seronegative for HCV RNA. The performance of the syphilis assay using the Ser-Col device is more uncertain since about a quarter of low serum positive subjects were not detected. These subjects had relatively weak positive results in serum suggesting old cured syphilis. However, a very recent infection would also be possible. Performance for syphilis screening was similar using the Ser-Col device and DBS. Even if the performance of screening for anti-treponemal antibodies on Ser-Col or DBS is lower than serum, this method of blood sampling could be useful for syphilis testing in the field. A trade-off between the analytical performances of the test and its accessibility in the field should be considered to evaluate the benefit of in-vitro diagnosis methods in the real world, as underlined in the guidelines of WHO [20, 21].

Our study has several limitations. First, we did not evaluate loss of follow up before participants obtained the results. This is an important aspect of screening strategies. Compared to POC tests, laboratory analyzes whether carried out on serum or dried blood samples entail a longer delay before the result is returned and therefore a greater risk of patient loss to follow-up before the test results are given to the patient [22]. Another limitation is the low number of positive subjects for HIV, HBV

and HCV infections even though a large number of participants were tested. Finally, we only performed qualitative tests, whereas quantitative results may be important for diagnosis of infectious diseases.

In conclusion, the Ser-Col device combined with an automated elution allows standardization and safety of the pre-analytical steps of analysis performed on dried blood samples. The clinical performances of the assays using the automated Ser-Col method appeared as good to those obtained with the DBS samples processed manually. Automated approaches to test capillary blood transported on dried blood devices are needed to enable testing of vulnerable population living outside healthcare facilities and facilitate large scale surveys assessing the burden of different infectious pathogens.

References:

1. **A Universal Truth: No Health Without a Workforce** [https://reliefweb.int/report/world/universal-truth-no-health-without-workforce]
2. Leslie HH, Spiegelman D, Zhou X, Kruk ME: **Service readiness of health facilities in Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United Republic of Tanzania**. *Bulletin of the World Health Organization* 2017, **95**(11):738-748.
3. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, Adeyi O, Barker P, Daelmans B, Doubova SV *et al*: **High-quality health systems in the Sustainable Development Goals era: time for a revolution**. *The Lancet Global health* 2018, **6**(11):e1196-e1252.
4. McLeod A, Weir A, Aitken C, Gunson R, Templeton K, Molyneaux P, McIntyre P, McDonald S, Goldberg D, Hutchinson S: **Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing**. *Journal of epidemiology and community health* 2014, **68**(12):1182-1188.
5. Shokoohi M, Karamouzian M, Khajekazemi R, Osooli M, Sharifi H, Haghdoost AA, Kamali K, Mirzazadeh A: **Correlates of HIV Testing among Female Sex Workers in Iran: Findings of a National Bio-Behavioural Surveillance Survey**. *PloS one* 2016, **11**(1):e0147587.
6. Foroughi M, Moayedi-Nia S, Shoghli A, Bayanolhagh S, Sedaghat A, Mohajeri M, Mousavinasab SN, Mohraz M: **Prevalence of HIV, HBV and HCV among street and labour children in Tehran, Iran**. *Sexually transmitted infections* 2017, **93**(6):421-423.
7. Bogowicz P, Moore D, Kanters S, Michelow W, Robert W, Hogg R, Gustafson R, Gilbert M: **HIV testing behaviour and use of risk reduction strategies by HIV risk category among MSM in Vancouver**. *International journal of STD & AIDS* 2016, **27**(4):281-287.
8. Douine M, Mosnier E, Le Hingrat Q, Charpentier C, Corlin F, Hureau L, Adenis A, Lazrek Y, Niemetsky F, Aucouturier AL *et al*: **Illegal gold miners in French Guiana: a neglected population with poor health**. *BMC public health* 2017, **18**(1):23.
9. Douine M, Musset L, Corlin F, Pelleau S, Pasquier J, Mutricy L, Adenis A, Djossou F, Brousse P, Perotti F *et al*: **Prevalence of Plasmodium spp. in illegal gold miners in French Guiana in 2015: a hidden but critical malaria reservoir**. *Malaria journal* 2016, **15**:315.
10. Douine M, Schaub R, Jardin H, Adenis A, Nacher M, Hureau-Mutricy L, Vreden S, Mosnier E, Pisoni A, Tuaillon E: **High prevalence of hepatitis B and syphilis in illegal gold miners in French Guiana**. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2019, **25**(8):1051-1053.
11. Gaillet M, Brousse P, Guarmit B, Adriouch L, Schaub R, Naldjinan-Kodbaye R, Carrera C, Lormée N, Simon T, Aubry Y *et al*: **Hépatites virales B - Delta et C dans les centres délocalisés de prévention et de soins (CPDS) de Guyane française**. *Bulletin de Veille Sanitaire - Cire Antilles Guyane* 2017:23-28.
12. Nacher M, Vantilcke V, Parriault MC, Van Melle A, Hanf M, Labadie G, Romeo M, Adriouch L, Carles G, Couppié P: **What is driving the HIV epidemic in French Guiana?** *International journal of STD & AIDS* 2010, **21**(5):359-361.
13. Nacher M, Adriouch L, Huber F, Vantilcke V, Djossou F, Elenga N, Adenis A, Couppié P: **Modeling of the HIV epidemic and continuum of care in French Guiana**. *PloS one* 2018, **13**(5):e0197990.
14. Moana G-S, Pierre M, Richard N, Marie-Josée L, Sandrine P-F, Laurent C, André C: **Tour d'horizon sur les hépatites chroniques B et C dans les départements-régions d'Outre-Mer et collectivités territoriales uniques**. *Hépato-Gastro & Oncologie Digestive* 2016, **23**(10):984-991.
15. **GLOBAL HEALTH SECTOR STRATEGY ON HIV 2016–2021TOWARDS ENDING AIDS** [https://www.who.int/publications/i/item/WHO-HIV-2016.05]
16. Meda N, Tuaillon E, Kania D, Tiendrebeogo A, Pisoni A, Zida S, Bollore K, Medah I, Laureillard D, Moles JP *et al*: **Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study**. *Bulletin of the World Health Organization* 2018, **96**(11):750-759.

17. Warszawski J, Beaumont AL, Seng R, de Lamballerie X, Rahib D, Lydié N, Slama R, Durrleman S, Raynaud P, Sillard P *et al*: **Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort**. *BMC infectious diseases* 2022, **22**(1):41.

18. Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, Ishizaki A, Nagarathnam A, Tuaillon E, van de Perre P *et al*: **Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses**. *BMC infectious diseases* 2017, **17**(Suppl 1):700.

19. Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, Messac L, Tuaillon E, van de Perre P, Pichler C *et al*: **Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis**. *BMC infectious diseases* 2017, **17**(Suppl 1):693.

20. World Health O, Centers for Disease C, Prevention, United States. Agency for International D, Global Fund to Fight Aids T, Malaria, African Society for Laboratory M: **Technical and operational considerations for implementing HIV viral load testing: interim technical update**. Geneva: World Health Organization; 2014.

21. **Guidelines on hepatitis B and C testing** [https://www.who.int/publications/i/item/9789241549981]

22. Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, Rougier H, Girard PM, Lacombe K: **Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage**. *Open forum infectious diseases* 2015, **2**(4):ofv162.

Figure 1.

Figure 1: Sampling location of the Orpal study in French Guiana. Large red shapes indicate illegal gold mining sites sites. Small circles on the Maroni and Oyapock rivers indicate collection sites that were located in resting places.

Figure 2.

Figure 2. Results of HIV, hepatitis B and hepatitis C testing on Ser-Col and DBS samples according to participant status. A) Results of HIV testing in Ser-Col samples and Dried blood Spot (DBS) according to HIV status in sera. B) Results of HBsAg testing in Ser-Col samples and Dried blood Spot (DBS) according to HBsAg status in sera. C) Results of hepatitis C antibody testing in Ser-Col samples and Dried blood Spot (DBS) according to anti-HCV status in sera. All samples tested positive for anti-HCV Abs were negative for HCV RNA.

Figure 3.

A

Figure 3. Anti-treponemal antibody results in Ser-Col and Dried Blood Spot samples. A) Anti-treponemal antibodies in and Ser-Col samples and Dried blood Spot (DBS) according to syphilis serological status in serum. B) Receiver operating characteristic curve (ROC) evaluating anti-treponemal antibody detection in Ser-Col samples. C) ROC evaluating anti-treponemal antibody detection in DBS samples.